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RecerXorVaaoDreesinAntagonistin Patientewith
ChronicHeartFailure -
W.T.Abraham, R.M. Oren, T.S. Crisman, A.D. Robertson, S. Shakar,
B.D. Lowes, L. Panther, P. Kelley, C.J. Pies, M.R. Bristow, R.W. Schrier.
Univeraifyof Colorado, Denvec CO, USA, The Universifyof Iowa, Iowa City
1A,USA
Vasopreaain (AVP) has been implicated in the renal water retention and di-
Iutional hyponatremia seen in chronic heari failure. However, the effects of
a selective renal, or V2, receptor AVP antagonist have not been previously
evaluated in human heart failure. Thus, we examined the effects of the oral,
nonpeptide, selaotive V2 receptor AVP antagonist WAY-VPA-985 (Wyeth-
Ayeret Research) in 21 patients with chronic NYHAclass II or Iii heati failure
(age 54 * 2 yrs, LVEF 21 + 2%) in a randomized, double-blind, placebo-
rmtrolled, ascending single dose study. After overnight fluid deprivation,
patients reoaivsd WAY-VPA-965at30 (n = 5), 75 (n = 5), or 150 mg (n = 5) or
a matching placebo (n = 8), followed by 4 hours of continued fluid restriction.
At all 3 doses, WAY-VPA-985 increased urine flow and serum sodium con-
centration. WAY-VPA-985also produced significant, dose-related, reductions
in urinary osmolality (see Fig.; p <0.0001 for doee effect pre-dose to 1.5
hours), thus indicating an increaae in solute-free water clearance.
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Conclusions: This fimt study of a selective W receptor AVP antagonist
in human heatt failure 1) supports the notion that plasma AVP is involved
in the impaired water excretion associated with chronic heart failure, and 2)
demonstrates that the nonpeptide V2 receptor AVPant.90niSt WAY-VPA-985
may be a promising therapeutic agent for the renal water retention of cardiac
failure.
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m7272 ChronicHamodynamicEffacteof Candoxatril:AMultl-CentreDoaaRangingStudy
J.G.F. Cleland, for the UK Candoxatril Haemodynamic Study Investigators.
University of Glaagow Glasgow, UK
Candoxatrtl is an inhibitor of neutral endopeptidase, a major clearance path-
way for natriuretic peptides, and ie natriuretic and improves exercise per-
formance in heart failure. No substantial placebo-controlled chronic haemo-
dynamic study is yet reperk% and the optimal therapeutic dose is not yet
established. Aooordingly we randomised 101 patients with predominantly
mild heart failure to raeaive, double-blind, placebo or cendoxatril in doses of
IO mg, 50 mg, 100 mg or 200 mg bd per day to investigate the effe~s on
rest and exeroiee haemodynamica (steady-state bicycle). Mean age wae 81
years, 8$ were men and 83 had ischaemic heart disease. All were receiving
conventional diuretics but 35 were not taking ACE inhibitors (protocol driven).
Baseline resting pulmonary capillary wedge pressure (PCWP) on placabo
was 17+ 5 mmHg (mean * SEM) and cardiac output 4.5 + 0.2 Umin, rising
on steady state exercise to 27 + 9 mmHg and 6.0+ 0.3 Umin, respectively.
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Candoxatril did not increase cardiac output at rest or during steady state ex-
ercise and the 10 mg and 50 mg doses exerted no affect on PCWP.However,
single doses of 100-200 mg reduced PCWP by 7 + 1 mmHg at rest and 8 +
3 mmHg and 9 + 2 mmHg, respectively during exercise (p <0.05 or more v.
placebo). During chronic administration candoxatril 100-200 mg bd did not
reduce resting PCWP significantly but reduced PCWP on exercise by 13 +
3 mmHg and 11 + 2 mmHg (p <0.05 v. placebo) during exercise at trough,
an OffSOfmaintained 6 houra after a further dose.
In patients with predominantly mild heart failure candoxatril lC&200 mg
bd reducesPCWPacutelyat restandon exercise and, during chronic therspy,
on exercise.
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WithChronicHeartFailureReceivingAngiotensin
ConvertingEnzymeInhibition
DE. Newby,T. McDonagh, P.F.Currie, N.A. Bmn, H.J. Dargie. Royal
Infirmary Edinburgh & Wastam Infirmary Glasgow, UK
Aims: To assess the effect of candoxatril, a novel neutral endopeptidase
(EC 24.11) inhibitor, on exercise capacity, clinical status and quality of life
in patients with mild to moderate chronic heart failure receiving angiotensin
converting enzyme inhibition.
Methods: Patients were recruited from 16 centres throughout the United
Kingdom. All patients had NYHA grade II or Ill chronic heart failure with
an ejection fraction of <ds~o or a shortening fraction of <20Y0, and were
receiving maintenanceangiotensin converting enzyme inhibitor therapy. They
were eligible for recruitment if their treadmill exercise tolerance was between
4 and 7 METS. Following a 4 week single blind placebo “run-in” phase
of weekly exercise tests, patients underwent double blind randomisation to
raeeive either candoxatril (100 mg bd) or placebo for the next 64 days.
Patients were then reassessed every 28 days.
Resu/ta: Of 110 patients randomised, 56 received candoxatril and 54
placebo. Over the study period, the overall improvement in mean total exer-
cise time in the cendoxatril group in comparison to the placebo group was
34.1 s (p = 0.02: 95Y0confidence intervals: 5.1 to 63.0). There were no
significant changes in functional class, clinical status or quality of life scores
between the two groups. There was a trend for a small reduction in blood
pressure in the candoxatril group.
Conclusion: Candoxatril confers an improvement in exercise capacity in
patients with chronic heart failure and represents a novel therapeutic adjunct
to ACE inhibition in these patients.
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ml ca~edilol,mProve.~efi en~ri~u,arRe9iona,w~l,
MotioninPatientswithHeartFailureof Ischemic
Etiology
R.N. Doughty, G. Whalley, G. Gamble, S. MacMahon, N. Sharpe, for the
Australia-New Zealand Heari Failure Research Collaborative Group.
University of Auckland School of Medicine, Auckland, New Zaaland
Beta-blocker therapy has been shown to increase LV ejeetion fraction and
to decrease LVvolumes in patients with heart failure of ischemic etiology. To
further investigate the mechanism of this improvement LV regional wall mo-
tion was assessed in a subgroup of 119participants from the ANZ Carvadllol
Heart Failure Study. In this trial, patients with chronic ischemic heart failure
on standard treatment including ACE inhibitor were randomized to treat-
ment with cervadilol (25-50 mg daily) or placebo. At baseline and after 6
and 12 months treatment, LV regional wall motion was aseessed from 2D-
echocerdiographic images using a semi-quantitative scoring syetem: graded
from 1 (normal) to 5 (aneurysmal), wall motion score index (WMSI) = total
score/no of segments visualized. Baseline WMSI inversely correlated with
baseline LV ejaetion fraction (r = –0.62, p = 0.0001). Baseline WMSI was
significantly lower in those patients who survived compared with thoee who
died (2.34vs2.47, 2P=0.04). Results for WMSl (mean + SE) with treatment:
n Baseline 6 Months 12months
Placebo 61 2.32+ 0,04 2S4 * 0,04 2.34* 0,05
Cawedilol 5s 2.40+ 0.03 2.29+ 0.03 2.29+ 004
2P(c VsP)<0.0001(BL-6M)<0.05 (BL-12M)
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Conclusion: LV regional wall motion appears to be of prognostic impor-
tance and is improved by carvedilol therapy. These data provide further
suppott for the beneficial effects of beta-blockade in patients with heart
failure.
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D7275 TheHemodynamicandNeurohumoralEffectsofMoxonidine,a SympatheticInhibitor,inCongestive
HeartFailure
K. Dickstein, U. K6PP,C. Manhenke, T. Aaraland, F.Waagstein, R. Mobini,
J. McNay. Central Hospital in Rogaland, Stavangen Norway
Sackgrourrd: Congestive heari failure is characterized by a pathologically
elevated peripheral vascular resistance and elevated noradrenaline (NA)
concentration. Chronic adrenergic stimulation may have deleterious effects
on the cardiovascular system. Moxonidine (MOX), via imidazoline receptor
agonism, reduces central empathetic outflow and circulating NA.
Lfetffcxfs:This study evaluated the neurohumoral and hemodynamic ef-
facfaof oral MOX in 30 patients (mean age 88 + 10 years) with NYHA class
Ill congestive heart failure. Mean ejection fraction was 28& 5%, mean pul-
monary capillary wedge preasura was 25 + 7 mmHg and mean NA was 505
+ 302 p@ml. Patients underwent 12 hour invasive hemodynamic monitoring
following blinded randomization to placebo (n = 12), 0.4 or 0.6 mg MOX (n =
18 combined). All other vasoacfive agents were withheld on the study day.
Results:
Changesfrombaaelineat 3 and6 hourspostdose.
MAP PCWP SVR NA
(mmHg) (mmHg) (dynes.sec.cm-5) (p@ml)
3 hoursPlacebo –0.6 –2.5 –49 8
MOX –13.3* –4.9* -154* -165**
6 hoursPlacebo 0.3 –2.1 4 –11
Mnx –12.S* –4.1* -21e* -lea**
lp <0.01, ** p< 0.005. MAP = Mean Arterial Pressure, PCWP = PulmonaryCapillary
Wedge Pressure, SVR = SystemicVascular Resistance, NA = Noradrenaline.
Conclusions: MOX was well tolerated and resulted in a modest, doae-
dependent vasodilator response. Substantial reductions in NA were ob-
served. These data suggest that moxonidine therapy may reduce vascular
resistance and improve the hemodynamic profile in patienta with CHF.
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m7276 ThePreventiveEffsotof AscorbateonNitrateTolerancein PatientswithCongestiveHeartFailure
H. Watanabe, M. Kakihanai, S. Ohtsuka, Y. Sugishita. University of
Tsukubs, Tsukubs,Japan, 1Ibaraki Pref&ursl University of Heakh
Sciences, Ibarski, Japan
The attenuation of intracellular cGMP has been known as an important
mechanism of nitrate tolerance. Recently, it was reported that increased
superoxide reduced the production of cGMP due to inactivation of guanylate
cyclase. This study was designad to investigate the effects of asoorbate,
an antioxidant of superoxide, on nitrate tolerance in patients with congestive
heart failure. Twelve patients with chronic heart failure admilfed toourhospital
for worsening symptoms were randomized to receive either an intravenous
infuaion of nitroglycerin (NTG) alone (1.5 @kg/rein [NTG group, n = 6])
or concomitantly with intravenous ascotiate (55 @kg/rein [NTG + Vit C
group; n =6]). Hemodynamic parameters and platelet cGMP were measured
aerially at the baseline, 6, 12, and 18 hours after the infusion of NTG alone or
NTG concomitantly with aacorbate. At the baseline, mean pulmonaw artery
pressure (PA, mmHg), mean pulmonary capillary wedge pressure (PCWP,
mmHg) and platelet cGMP (pmol/109 PLT) level were comparable in the two
groups. At6 hours,PAandPCWPweresignificantlydecreased(NTGgroup,
PA: 4S + 3 to 26 + 3, p < 0.05; PCWP: 25 + 4 to 15+2, p < 0.05; NTG +
Vit C group, PA: 49 + 3 to 26 &3, p e 0.05; PCWP: 24 + 4 to 16 + 3, p <
0.05), and platelet cGMp was significantly elevated (NTG group, 0.76+0.12
to 2.42+0.24, p < 0.05; NTG + Vit C group, 0.71 + 0.16 to 2.26 &0.37, p <
0.05). At 12 hours, the effects of NTG onPA,PCWPandplateletcGMPwere
maintained.However,at 18 hours,in the NTGgroup,PAand PCWPwere
elevated(PA:44 * 3, PCWP:23 * 3) and plateletcGMPwasdecreased
(0.S5+ 0.20).In contrast,in the NTG+ Vit C group,NTGeffectsin PA.(3I
+ 4), PCWP(17 + 4) and plateletcGMP(2.49* 0.42)were maintained
throughouthisstudy.
Cone/usiona:These results indicated that the concomitant use of ascor-
bate may prevent the development of nitrate tolerance in patients with hearl
failure treatad with NTG.
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n7281 A MulticenterRandomizedTrialComparingthe
SscondGenerationGianturco-Roubin(GRIIT”)and
the Palmaz-SchatzCoronaryStents
Multicenter GRIIWInvestigator Group, M. Leon. Washington Hospita/
Center, Washington, DC, USA
Direct comparisons of clinical outcomes for two stent designa in a random-
ized trial eliminate the confounding influences of differing patient selection
criteria and indications for use. The second generation Gianturco-Roubin
(GRII”’) balloon-expandable coronary stent (20 and 40 mm lengths), with a
flat wire clamshell deeign, Iowprofile, and radio-opaque end-markers is baing
compared to the commercially available Palmaz-Schatz (PS) tubular slotted
(15 mm length). Enrollment criteria include patients undergoing successful
elective PTCA of de novo lesions with reference vessel size 2-4 mm and
lesion length <30 mm. For longer lesions which could not be mverad by a
single 15 mm PSor20 mm GRII’” stent, two PSortwo20 mm GRII’” orone40
mm GRII’” stent is permitted. Patients with recent Ml (<7days), LVEF < 35%,
poor distal run-off, or residual thrombus in the target lesion are excluded.
A sample size of 750 patients (375 per arm) was chosen to demonstrate
equivalerl rates of freedom from major cardiac events (death, Q-Ml, CABG,
repeat PTCA) @ 9 months follow-up (primary end-point). Other important
endpoints include quantitative angiographic analyses (follow-up minimum
lumen diameter and binary restenosis) @ 9 months, in-hoepital prccadure
succeas and major clinical events, and 30-day major clinical events. Since
January 1996, 31 investigator sites have enrolled 595 patienta (302 GRII’”
and 293 PS) and enrollment is nearing completion. Comparative ana/yses of
procedural results (including quantitatim angiographic findings), in-hospital
major clinical events, and30-day clinical outcomes will bepreserrted.
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1728-21 BENESTENT-llTrial-Final resultsof Viait1:A
15-DayFollow-Up
V. Legrand, P.W. Serruys, H. Emanuelsson, J. Fajadet, M. Hautie,
S. Klugmann, F. Bar, F. Fernandez-Aviles, H. Suryapranata, M.A. Morel.
Thoraxcentec Rotterdam, NL
The BENESTENT41Trial is a randomized trial comparing the outcome after
balloon angioplasty, with the effect of Heparin-coatad Palmaz-Schafz stent
(10, 15 and 20 mm long with one or multiple helicoidal articulations) on
the long-term effect of Major Adverse Cardiac Events (MACE: Death, Ml,
Target Lesion Revascularisation ~LR]), in patients with stable or stabilized
unstable angina pectoris with one or more de novo lesions. The secondary
objectives are to assess the Cost-effectiveness and the restenosis rate. To
that purpcse a 1:1aub-randomization to either clinical or angiographic follow-
UPwas carried out. Concomitant medications consist of Aspirin (?100 mg)
and Ticiopidin (250 mg, 30 days) in the stent group. Between August 28th
’95 and March 7th ’96, 827 patients were randomized to either treatment
with stent (414) or balloon (413). Forty-three percent of the patients had
unstable angina, 51% atable and 6% silent ischemia. 6% underwent multiple
lesion treatment. 54% of the lesions were B2 lesions (AHA/ACC). In the
balloon group 13.4% of the patients received a bail-out stent according to
preset atringent criteria: procedural success is 97% in the stent group and
86% in the balloon group according to the actual allocation protocol. The
hospital atay in the stent group was 2.4 days vs 2.1 days in the balloon
group, Subacute occlusion was observed in one patient in the atent group
vs,7 patients in the balloon group. Bleeding and vaacular complications in
both groups were low (0.7 vs 0.5%). At 15 days Fup, the total count of
MACE amounts to 4.3% (n = 18) in the stent group vs 6.5% (n = 27) in
the balloon group. Sixteen patients in the stent group (3.9%) vs 18 (4.4%)
in the balloon group have at least one event. In 10 patienta the Ticlopidin
was stoppad because of adverse reaction, but no Ieucopenia, neutropenia,
thrombocytopenia was observed. The MLD achieved in the stent group wee
2.69 mm vs 2.15 mm in tha balloon group. Based on the acute QCA results
and applying a validated multivariate analysis derived from Benestent-1,we
expect significant differences in Restenosis rate (13% va 28%) and in event
rates at follow-up. It remains to be demonstrated whether elective stenting
will be at long-term more coet-effective than balloon.
